Kairos Pharma to Present at DealFlow Discovery Conference as Oncology Programs Advance

Kairos Pharma announced its participation in the DealFlow Discovery Conference scheduled for January 28-29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, New Jersey. The company's Chief Scientific Officer Neil Bhowmick will deliver a company presentation and conduct one-on-one meetings with investors during the event. This participation comes as Kairos continues advancing its clinical-stage oncology programs, which represent significant developments in cancer therapeutics.

The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. These trials address significant unmet medical needs in oncology, where drug resistance remains a major challenge in cancer treatment.

Kairos Pharma utilizes structural biology to overcome drug resistance and immune suppression in cancer, positioning the company at the forefront of oncology therapeutics. The company's approach focuses on developing treatments that can work in conjunction with existing standard therapies rather than replacing them entirely. This strategy could potentially extend the effectiveness of current cancer treatments and improve patient outcomes across various cancer types where resistance develops.

The DealFlow Discovery Conference provides an important platform for Kairos to engage with investors and communicate its progress. Investor conferences serve as critical venues for emerging biotechnology companies to showcase their scientific advancements and clinical progress. For more information about Kairos Pharma's latest developments, the company maintains a newsroom available at https://ibn.fm/KAPA. The conference participation represents an opportunity for the company to demonstrate the potential of its approach to addressing drug resistance in cancer treatment.

As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The clinical trials are ongoing, and their outcomes will determine the future development path for the company's lead candidate. The company's participation in investor conferences like the DealFlow Discovery Conference helps maintain visibility within the investment community as these clinical programs progress through development stages.